Alivus Life Sciences Ltd (NSE:ALIVUS)

Q1 2026 Alivus Life Sciences Ltd Earnings Call Transcript

Aug 1, 2025 / 03:00 AM GMT

Transcript

Key Points

Positve

Alivus Life Sciences Ltd (BOM:543322) reported a year-on-year revenue growth of 2.2%, driven by a 14.5% increase in the non-GPL business.
The company's gross margin improved by 400 basis points to 55.1%, attributed to rationalized input costs and operational efficiency.
The EBITDA margin increased by 210 basis points to 30.1%, reflecting better gross margins.
Alivus Life Sciences Ltd (BOM:543322) remains debt-free and generated strong cash flow from operations, with cash and cash equivalents of INR 660 crore.
The company received successful outcomes from US FDA inspections for its facilities, enhancing its compliance and operational credibility.

Negative

The GPL business experienced a significant year-on-year decline of 22%, impacting overall revenue growth.
The CDMO business remained subdued during the quarter, with commercialization expected only in the second half of the year.
Pricing pressures are anticipated to keep revenue growth in the high single digits, despite mid-teens volume growth guidance.
The company's R&D expenditure increased, which may impact short-term profitability.
There is uncertainty regarding the timeline for product commercialization from the Solapur facility, which could delay revenue contributions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALIV.NS - Alivus Life Sciences Ltd
Q1 2026 Alivus Life Sciences Ltd Earnings Call
Aug 02, 2025 / 03:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Eliance Life Sciences Limited, Q1F5 26 earnings conference call. As a reminder, all participant lines will be in the lesson only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing start and 0 and it rested on 4. Please note that this conference is being recorded.

I now hand the conference over to Miss Sumirao, Alives Life Sciences Limited.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.